1,092 results

#121675-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Dec. 15, 2020

Academic Institutions and Nonprofits only

#26971-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-eNpHR 3.0-EYFP (#26971). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-eNpHR 3.0-EYFP plasmid DNA. CaMKIIa-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 14, 2018

Academic Institutions and Nonprofits only

#183535-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-Flpo (#183535). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-Flpo plasmid DNA. CamKIIa-driven expression of Flpo recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fan et al Cell. 2023 Feb 2;186(3):543-559.e19. doi

Oct. 8, 2025

Academic Institutions and Nonprofits only

#104492-AAV8

Ready-to-use AAV8 particles produced from pGP-AAV-syn-FLEX-jGCaMP7f-WPRE (#104492). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7f-WPRE plasmid DNA. Syn-driven, Cre-dependent GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

May 29, 2019

Academic Institutions and Nonprofits only

#179464-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-JEDI-2P-WPRE (#179464). In addition to the viral particles, you will also receive purified pAAV-hSyn-JEDI-2P-WPRE plasmid DNA. hSyn-driven expression of the genetically encoded voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Jan. 24, 2024

Academic Institutions and Nonprofits only

#203841-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH (#203841). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of mutant murine Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 9, 2026

Academic Institutions and Nonprofits only

#203840-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 6, 2026

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#50465-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#20298-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 30, 2018

Academic Institutions and Nonprofits only